Document Detail

Spontaneous pneumomediastinum secondary to refractory dermatomyositis successfully treated with rituximab.
MedLine Citation:
PMID:  20195881     Owner:  NLM     Status:  MEDLINE    
Spontaneous pneumomediastinum has been described in patients with dermatomyositis (DM) and polymyositis (Korkmaz et al., Rheumatology 40:476-478, 2001; Maruoka et al., Mod Rheumatol 16:55-57, 2006; Kono et al., Ann Rheum Dis 59:372-376, 2000; Neves et al., Clin Rheumatol 26:105-107, 2007). Literature reviews suggest that this complication has a mortality of between 27% and 41% ( Kono et al., Ann Rheum Dis 59:372-376, 2000; Neves et al., Clin Rheumatol 26:105-107, 2007; Goff et al., Arthritis Rheum 61:108-118, 2009). This is the first report of rituximab being used successfully as part of the treatment for DM complicated by pneumomediastinum.
Martin A Lee; David G Hutchinson
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-03-01
Journal Detail:
Title:  Clinical rheumatology     Volume:  29     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-02     Completed Date:  2010-10-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  945-6     Citation Subset:  IM    
Rheumatology Department, Royal Devon & Exeter Hospital, Exeter, Devon, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Dermatomyositis / complications*
Mediastinal Emphysema / drug therapy*,  etiology*
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Juvenile idiopathic arthritis among Nigerians: a case study.
Next Document:  Determination of teicoplanin trough concentration target and appropriate total dose during the first...